Non-Cystic Fibrosis Bronchiectasis Market

Non-cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production and recurrent pulmonary infections. The changes in the bronchial walls may be due to chronic inflammation secondary to recurrent or chronic infections in the lung, but often the exact cause is not identified.1 Symptoms vary from intermittent episodes of respiratory infections with excessive mucus production to chronic symptoms with persistent daily expectoration of purulent sputum. Non-cystic fibrosis bronchiectasis is associated with comorbidities such as anxiety, depression, fatigue, and has a significant impact on quality of life.

Non-Cystic Fibrosis Bronchiectasis Market contains market size and forecasts of Non-Cystic Fibrosis Bronchiectasis in Global, including the following market information:

• Global Non-Cystic Fibrosis Bronchiectasis Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Non-Cystic Fibrosis Bronchiectasis market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Non-Cystic Fibrosis Bronchiectasis include Aradigm Corporation, Zambon, Novartis Pharmaceuticals and Insmed Incorporated, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Non-Cystic Fibrosis Bronchiectasis companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Non-Cystic Fibrosis Bronchiectasis Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Non-Cystic Fibrosis Bronchiectasis Market Segment Percentages, by Type, 2021 (%)

• Oral
• Intravenous

Global Non-Cystic Fibrosis Bronchiectasis Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Non-Cystic Fibrosis Bronchiectasis Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Others

Global Non-Cystic Fibrosis Bronchiectasis Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Non-Cystic Fibrosis Bronchiectasis Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Non-Cystic Fibrosis Bronchiectasis revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Non-Cystic Fibrosis Bronchiectasis revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Aradigm Corporation
• Zambon
• Novartis Pharmaceuticals
• Insmed Incorporated